Once the appropriate TCR is isolated and cloned, a viral vector encoding the designated TCR can be used to transduce T lymphocytes isolated from any patients sharing the same HLA molecule. A patient receives a brief chemo conditioning of peripheral blood, followed by re-infusion of the engineered T cells that identify and bind to tumor-derived peptides displayed by the patient’s HLA molecules, thereby triggering an immune response and killing the cancerous cells.